The two pipelines used to quantify brain PET imaging (CapAIBL and CL‐SPM) generated consistent results in quantifying tau scans in all ROIs, with high discriminative power in distinguishing AD Aβ+ from CU Aβ− and tau negative scans from limbic predominant, hippocampal sparing, and typical AD tau scans when using a threshold of > 2 CTRz in different ROIs. This evidence concerns the gene MAPT and Alzheimer disease.